BRPI0908627A2 - processo para se produzir moléculas escolhidas entre as das fórmulas (iia), (iib), (iic) e (iii), molécula de fórmula (iia), (iib), (iic), (iii), (iv) e (v), processo para produzir uma molécula que corresponde à formula (v), (vi), ou (vii), moléculas, composição farmacêutica e uso de uma composição - Google Patents

processo para se produzir moléculas escolhidas entre as das fórmulas (iia), (iib), (iic) e (iii), molécula de fórmula (iia), (iib), (iic), (iii), (iv) e (v), processo para produzir uma molécula que corresponde à formula (v), (vi), ou (vii), moléculas, composição farmacêutica e uso de uma composição

Info

Publication number
BRPI0908627A2
BRPI0908627A2 BRPI0908627A BRPI0908627A BRPI0908627A2 BR PI0908627 A2 BRPI0908627 A2 BR PI0908627A2 BR PI0908627 A BRPI0908627 A BR PI0908627A BR PI0908627 A BRPI0908627 A BR PI0908627A BR PI0908627 A2 BRPI0908627 A2 BR PI0908627A2
Authority
BR
Brazil
Prior art keywords
iic
iib
iia
iii
formula
Prior art date
Application number
BRPI0908627A
Other languages
English (en)
Inventor
Alain Fournet
Anh Tuan Lormier
Bernardin Akagah
Bruno Figadere
Original Assignee
Alpha Chimica
Inst Rech Developpement Ird
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Chimica, Inst Rech Developpement Ird filed Critical Alpha Chimica
Publication of BRPI0908627A2 publication Critical patent/BRPI0908627A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0908627A 2008-05-20 2009-05-15 processo para se produzir moléculas escolhidas entre as das fórmulas (iia), (iib), (iic) e (iii), molécula de fórmula (iia), (iib), (iic), (iii), (iv) e (v), processo para produzir uma molécula que corresponde à formula (v), (vi), ou (vii), moléculas, composição farmacêutica e uso de uma composição BRPI0908627A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0802745A FR2931479B1 (fr) 2008-05-20 2008-05-20 Nouveaux derives de quinoleines 2-substituees et un procede pour leur preparation
PCT/FR2009/000573 WO2009150318A1 (fr) 2008-05-20 2009-05-15 Nouveaux derives de quinoleines 2-substituees et un procede pour leur preparation

Publications (1)

Publication Number Publication Date
BRPI0908627A2 true BRPI0908627A2 (pt) 2015-09-15

Family

ID=40149587

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908627A BRPI0908627A2 (pt) 2008-05-20 2009-05-15 processo para se produzir moléculas escolhidas entre as das fórmulas (iia), (iib), (iic) e (iii), molécula de fórmula (iia), (iib), (iic), (iii), (iv) e (v), processo para produzir uma molécula que corresponde à formula (v), (vi), ou (vii), moléculas, composição farmacêutica e uso de uma composição

Country Status (5)

Country Link
US (1) US20120225903A1 (pt)
EP (1) EP2291381A1 (pt)
BR (1) BRPI0908627A2 (pt)
FR (1) FR2931479B1 (pt)
WO (1) WO2009150318A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE282457C (pt) *
US4440771A (en) * 1982-02-12 1984-04-03 The United States Of America As Represented By The Secretary Of The Army 2-Acetyl quinoline thiosemicarbazones useful in treatment of gonorrhea, malaria or bacterial infections
FR2682107B1 (fr) * 1991-10-03 1995-04-21 Orstom Inst Fs Rech Scient Quinoleines 2-substituees pour le traitement des leishmanioses.
FR2819507B1 (fr) * 2001-01-17 2007-09-28 Inst Rech Developpement Ird Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
EP1734939A4 (en) * 2004-03-05 2010-06-30 Univ California PEST CONTROL COMPOUNDS AND METHODS OF USE

Also Published As

Publication number Publication date
US20120225903A1 (en) 2012-09-06
FR2931479B1 (fr) 2012-12-07
WO2009150318A1 (fr) 2009-12-17
FR2931479A1 (fr) 2009-11-27
EP2291381A1 (fr) 2011-03-09

Similar Documents

Publication Publication Date Title
MA30236B1 (fr) Nouvelle composition pharmaceutique
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
BR112012032244A2 (pt) processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes
DOP2011000172A (es) Compuestos organicos
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
BRPI0916069C1 (pt) composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição
ECSP10010722A (es) Compuestos orgánicos
ECSP11011184A (es) Compuestos orgánicos
DOP2011000176A (es) Compuestos organicos
BRPI0618933A2 (pt) método para produzir uma molécula efetora que se liga à queratina, molécula efetora que se liga à queratina, uso das moléculas efetoras que se ligam à queratina, composto, e, dermocosmético
DK2227476T3 (da) Tricykliske triazoliske forbindelser
BR112012021771A2 (pt) métodos de uso de inibidores de contransportadores de sódio-glicose 1 e 2.
GB0508318D0 (en) Organic compounds
JO2770B1 (en) Organic compounds
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
CL2008001393A1 (es) Compuestos derivados de dihidroquinonas y dihidronaftiridinas, inhibidores de jnk; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar artritis reumatoide, asma, diabetes tipo 2, alzheimer, enfermedad de parkinson, hiperproliferacion celular.
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
BRPI0814457A2 (pt) Derivados de imidazolona, composições farmacêuticas, utilização de derivados de imidazolona, e, processo de síntese de derivados de imidazolona
DE602006009789D1 (de) Acetylenderivate
BRPI0818736A2 (pt) composições e métodos para intensificar imunorrepostas à bactéria flagelada
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
BRPI0809708A2 (pt) "processo multiestágio para a preparação de uma composição de (co) polímero"
BRPI0812166A2 (pt) Composições úteis para reduzir nefrotoxicidade e métodos de uso das mesmas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.